CRA consultants analyzed market power and alleged anticompetitive conduct for a CNS therapy. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing. Also considered were effects on demand resulting from the change in the form of competition upon the launch of generic products.
CRA Sessions: AI in Practice | Copyright in the age of AI: Following the evidence
A historic $1.5 billion settlement by Anthropic delivered the first significant judicial ruling on the issue. The ruling is expected to influence how courts,...